These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 15930318

  • 1. Tumor-infiltrating dendritic cell subsets of progressive or regressive tumors induce suppressive or protective immune responses.
    Liu Y, Bi X, Xu S, Xiang J.
    Cancer Res; 2005 Jun 01; 65(11):4955-62. PubMed ID: 15930318
    [Abstract] [Full Text] [Related]

  • 2. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T, Iwahashi M, Nakamura M, Matsuda K, Naka T, Nakamori M, Ueda K, Ishida K, Yamaue H.
    Int J Oncol; 2006 Apr 01; 28(4):947-53. PubMed ID: 16525645
    [Abstract] [Full Text] [Related]

  • 3. Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity.
    Hokey DA, Larregina AT, Erdos G, Watkins SC, Falo LD.
    Cancer Res; 2005 Nov 01; 65(21):10059-67. PubMed ID: 16267032
    [Abstract] [Full Text] [Related]

  • 4. Murine dendritic cells pulsed with an anti-idiotype antibody induce antigen-specific protective antitumor immunity.
    Saha A, Chatterjee SK, Foon KA, Primus FJ, Bhattacharya-Chatterjee M.
    Cancer Res; 2003 Jun 01; 63(11):2844-54. PubMed ID: 12782590
    [Abstract] [Full Text] [Related]

  • 5. Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses.
    Yang AS, Lattime EC.
    Cancer Res; 2003 May 01; 63(9):2150-7. PubMed ID: 12727833
    [Abstract] [Full Text] [Related]

  • 6. CD4+ Th2 cells function alike effector Tr1 and Th1 cells through the deletion of a single cytokine IL-6 and IL-10 gene.
    Ankathatti Munegowda M, Xu S, Freywald A, Xiang J.
    Mol Immunol; 2012 Jun 01; 51(2):143-9. PubMed ID: 22424785
    [Abstract] [Full Text] [Related]

  • 7. CD40 ligation converts TGF-beta-secreting tolerogenic CD4-8- dendritic cells into IL-12-secreting immunogenic ones.
    Zhang X, Kedl RM, Xiang J.
    Biochem Biophys Res Commun; 2009 Feb 20; 379(4):954-8. PubMed ID: 19135981
    [Abstract] [Full Text] [Related]

  • 8. CD4+ T cells are able to promote tumor growth through inhibition of tumor-specific CD8+ T-cell responses in tumor-bearing hosts.
    den Boer AT, van Mierlo GJ, Fransen MF, Melief CJ, Offringa R, Toes RE.
    Cancer Res; 2005 Aug 01; 65(15):6984-9. PubMed ID: 16061684
    [Abstract] [Full Text] [Related]

  • 9. Optimal TLR9 signal converts tolerogenic CD4-8- DCs into immunogenic ones capable of stimulating antitumor immunity via activating CD4+ Th1/Th17 and NK cell responses.
    Zhang X, Munegowda MA, Yuan J, Wei Y, Xiang J.
    J Leukoc Biol; 2010 Aug 01; 88(2):393-403. PubMed ID: 20466823
    [Abstract] [Full Text] [Related]

  • 10. Termination of systemic immunity in the presence of intraocular tumors: influence of ocular immune privilege on tumor vaccines.
    Chen PW, Ksander BR.
    Curr Eye Res; 2006 Jan 01; 31(1):43-55. PubMed ID: 16421019
    [Abstract] [Full Text] [Related]

  • 11. [Immunotherapeutic efficacy of both helper T lymphocytes and cytotoxic T lymphocytes epitopes augmented dendritic cells tumor vaccine on gastric cancer].
    Li Q, Zhang Y, Chen XH, Cao WX, Gu QL, Zhu ZG, Liu BY.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Mar 01; 9(2):148-51. PubMed ID: 16555158
    [Abstract] [Full Text] [Related]

  • 12. Repeated restraint stress impairs the antitumor T cell response through its suppressive effect on Th1-type CD4+ T cells.
    Li T, Harada M, Tamada K, Abe K, Nomoto K.
    Anticancer Res; 1997 Mar 01; 17(6D):4259-68. PubMed ID: 9494518
    [Abstract] [Full Text] [Related]

  • 13. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts.
    Gabrilovich DI, Ciernik IF, Carbone DP.
    Cell Immunol; 1996 May 25; 170(1):101-10. PubMed ID: 8665590
    [Abstract] [Full Text] [Related]

  • 14. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A, Chatterjee SK, Foon KA, Celis E, Bhattacharya-Chatterjee M.
    Cancer Res; 2007 Mar 15; 67(6):2881-92. PubMed ID: 17363612
    [Abstract] [Full Text] [Related]

  • 15. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.
    Huang H, Li F, Gordon JR, Xiang J.
    Cancer Res; 2002 Apr 01; 62(7):2043-51. PubMed ID: 11929823
    [Abstract] [Full Text] [Related]

  • 16. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.
    Cao DY, Yang JY, Dou KF, Ma LY, Teng ZH.
    Hum Immunol; 2007 May 01; 68(5):334-41. PubMed ID: 17462500
    [Abstract] [Full Text] [Related]

  • 17. Dendritic cells generated in the presence of interferon-alpha stimulate allogeneic CD4+ T-cell proliferation: modulation by autocrine IL-10, enhanced T-cell apoptosis and T regulatory type 1 cells.
    Carbonneil C, Saidi H, Donkova-Petrini V, Weiss L.
    Int Immunol; 2004 Jul 01; 16(7):1037-52. PubMed ID: 15184347
    [Abstract] [Full Text] [Related]

  • 18. Dendritic cells pulsed with an anti-idiotype antibody mimicking carcinoembryonic antigen (CEA) can reverse immunological tolerance to CEA and induce antitumor immunity in CEA transgenic mice.
    Saha A, Chatterjee SK, Foon KA, Primus FJ, Sreedharan S, Mohanty K, Bhattacharya-Chatterjee M.
    Cancer Res; 2004 Jul 15; 64(14):4995-5003. PubMed ID: 15256474
    [Abstract] [Full Text] [Related]

  • 19. Characterization of tumor-infiltrating CD4+ T cells as Th1 cells based on lymphokine secretion and functional properties.
    Nagarkatti M, Clary SR, Nagarkatti PS.
    J Immunol; 1990 Jun 15; 144(12):4898-905. PubMed ID: 1972170
    [Abstract] [Full Text] [Related]

  • 20. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
    Ye Z, Tang C, Xu S, Zhang B, Zhang X, Moyana T, Yang J, Xiang J.
    Cell Mol Immunol; 2007 Aug 15; 4(4):277-85. PubMed ID: 17764618
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.